Weekly Ophthalmic Newsletter

1. Researchers Introduce Algae-Derived Solution for Retinal Detachment

A recent study has introduced an innovative approach to treating retinal detachment through an artificial vitreous body made from alginate, a natural carbohydrate extracted from algae. This research represents a collaboration among experts from Pohang University of Science and Technology and Dong-a University Hospital , showcasing a promising alternative to conventional intraocular fillers that often come with side effects.

The creation of the hydrogel aims to combat the challenges associated with retinal detachment—a condition that can lead to blindness if not properly addressed. Traditional treatments involve the replacement of the eye's gel-like vitreous body with materials that might cause complications.

Click here to read the full article.

2. Nanoscope Announces Positive Results in RP Treatment with MCO-010 Gene Therapy

Nanoscope Therapeutics Inc. announced positive topline results from the phase 2b RESTORE trial, evaluating MCO-010, a novel gene therapy aimed at treating severe vision loss caused by advanced retinitis pigmentosa (RP), irrespective of the genetic mutation causing the disease.

MCO-010's safety profile is equally impressive, with no serious or severe adverse events related to the treatment reported. The therapy's most common side effects were mild or moderate and primarily involved the anterior chamber of the eye.

Click here to read the full article.

3. Regenxbio's Gene Therapy for Wet AMD Shows Promising Results in The Lancet

REGENXBIO announced the publication of their phase 1/2a study results in The Lancet, showcasing the effectiveness of ABBV-RGX-314 as a one-time gene therapy for wet age-related macular degeneration (AMD).

The study, titled "Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study," provides compelling two-year data supporting the safety and tolerability of a single dose of ABBV-RGX-314.

Click here to read the full article.

4. Opus Genetics Advances with Novel LCA5 Gene Therapy in Phase 1/2 Clinical Trial

Opus Genetics recently completed the first stage of its innovative clinical trial, focusing on a new treatment for patients suffering from Leber congenital amaurosis (LCA) due to biallelic mutations in the LCA5 gene.

The trial, which is in the phase 1/2 stage, tests the efficacy of OPGx-LCA5, a therapy involving the subretinal delivery of a functional LCA5 gene using an adeno-associated virus 8 (AAV8) vector. The initial group, comprising three adult participants, has successfully received their doses, paving the way for the next phase of research.

Click here to read the full article.

5. Iveric Bio Awarded Permanent J-code for GA Treatment, Izervay

In a significant development for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), Iveric Bio, An Astellas Company has been granted a unique, permanent J-code by the Centers for Medicare & Medicaid Services (CMS) for its innovative treatment, Izervay (avacincaptad pegol intravitreal solution).

Marking a pivotal moment in the healthcare and pharmaceutical landscape, the assignment of J-code J2782, effective from April 1, 2024, heralds a new era in the streamlined billing and reimbursement process for this vital treatment.

Click here to read the full article.

Also, check this out...

Don't Miss Out: ASCRS Congress 2024 Kicks Off This April 5-8

From April 5 to 8, 2024, the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting is set to take place in Boston, USA, at the Boston Convention & Exhibition Center.

This annual meeting is a pivotal event for professionals in the field of anterior segment surgery, offering a comprehensive program designed to enhance clinical knowledge, surgical skills, and business acumen. Set against the backdrop of a dynamic educational environment, the congress promises to bring together the brightest minds in ophthalmology, providing opportunities for learning, networking, and discovery.

Click here to learn more about the Congress.

If you want to stay updated with the latest news via e-mail, click here to subscribe.